Document Detail

Interactions between cocaine and dopamine agonists on cardiovascular function in squirrel monkeys.
MedLine Citation:
PMID:  11752114     Owner:  NLM     Status:  MEDLINE    
Conscious squirrel monkeys were treated i.v. with cocaine and various dopamine agonist drugs. Cocaine produced a dose-dependent increase in blood pressure, heart rate, and the rate-pressure product (RPP). The dopamine D1 receptor agonist (+/-)-6-chloro-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (SKF 82958) produced effects comparable to cocaine. The D1 agonist (+/-)-6-chloro-7, 8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (SKF 81297) also produced increases in blood pressure and heart rate but was much less potent than either cocaine or SKF 82958. The partial D1 agonist (+/-)-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SKF 77434) did not significantly affect any cardiovascular parameters. The D2 agonist quinpirole slightly decreased blood pressure and increased heart rate. As such, the RPP only slightly increased. The selective dopamine uptake inhibitor 1-[2-[bis-(4-fluorphenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909) produced increases in blood pressure, heart rate, and RPP, but again these effects were smaller and only seen at doses higher than cocaine. Effects similar to those with GBR 12909 were seen with the dopamine autoreceptor antagonist cis-(+)-5-methoxy-1-methyl-2-(di-n-propylamino)tetralin (UH 232). The combination of GBR 12909, SKF 82958, or SKF 77434 with cocaine produced effects that were clearly subadditive. The effects of quinpirole in combination with cocaine were comparable to, or lower than, those of cocaine alone on blood pressure and RPP. The effects on heart rate were additive. Only UH 232 produced additive effects with cocaine for all three measures. As dopamine agonists have been proposed as potential treatments for cocaine abuse, these results suggest that dopamine D1 agonists and uptake inhibitors can be used safely in combination with cocaine. Caution may be warranted, however, with the use of dopamine autoreceptor antagonists in the treatment of cocaine abuse.
C W Schindler; J P Gilman; J Bergman; N K Mello; R L Woosley; S R Goldberg
Related Documents :
24155554 - Effect of pinpoint plantar long-wavelength infrared light irradiation on subcutaneous t...
6822144 - The effect of intravenous clonidine hydrochloride on the isolated forearm venous segmen...
9756044 - Ethanol counteraction of clonidine-evoked inhibition of norepinephrine release in rostr...
1739234 - Increased sympathetic nervous activity and the effects of its inhibition with clonidine...
10782814 - Altered function of the hypothalamic stress axes in patients with moderately active sys...
9040634 - Swine lungs expressing human complement-regulatory proteins are protected against acute...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The Journal of pharmacology and experimental therapeutics     Volume:  300     ISSN:  0022-3565     ISO Abbreviation:  J. Pharmacol. Exp. Ther.     Publication Date:  2002 Jan 
Date Detail:
Created Date:  2001-12-25     Completed Date:  2002-01-24     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0376362     Medline TA:  J Pharmacol Exp Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  180-7     Citation Subset:  IM    
Preclinical Pharmacology Section, Behavioral Neuroscience Branch, National Institutes of Health/National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland 21224, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure / drug effects
Cocaine / pharmacology*
Dopamine Agonists / pharmacology*
Dopamine Antagonists / pharmacology
Dopamine Uptake Inhibitors / pharmacology*
Drug Interactions
Heart Rate / drug effects
Hemodynamics / drug effects*
Receptors, Dopamine D1 / agonists
Receptors, Dopamine D2 / agonists
Grant Support
Reg. No./Substance:
0/Dopamine Agonists; 0/Dopamine Antagonists; 0/Dopamine Uptake Inhibitors; 0/Receptors, Dopamine D1; 0/Receptors, Dopamine D2; 50-36-2/Cocaine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Multiple specific binding targets for inhaled anesthetics in the mammalian brain.
Next Document:  Regulation of cyclooxygenase by the heme-heme oxygenase system in microvessel endothelial cells.